

**REMARKS**

Claims 1, 3-11 are pending and under consideration following Applicants' response mailed October 3, 2007. The Communication dated October 29, 2007, alleges that Applicants' amendment to claim 1 changes the invention from the one originally elected. Applicants respectfully disagree. The claims always had the proper abbreviation, i.e. IGF-1R, and merely omitted the term "receptor" had merely been accidentally omitted. As the Examiner himself observed in the Office Action dated April 4, 2007, the specification discloses throughout that the IGF-1R binds disease specific IgG. See Office Action mailed April 4, 2007, para. bridging pp. 6 and 7. Accordingly, given that the claims are read and interpreted in light of the specification and that the proper abbreviation for the IGF-1 receptor was recited in the original claims, it is submitted to be evident that the omission of receptor was merely a typographical omission. Applicants respectfully request that prosecution be continued with the corrected claims set and thank the Examiner for his time and courtesy.

**CONCLUSION**

In light of the amendments and remarks herein, Applicants submit that the claims are now in condition for allowance and respectfully request a notice to this effect. The Examiner is invited to call the undersigned attorney if there are any questions.

To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

/Astrid R. Spain/

Astrid R. Spain  
Registration No. 47,956

**Please recognize our Customer No. 41552  
as our correspondence address.**

4370 La Jolla Village Drive, Suite 700  
San Diego, CA 92122

Phone: 858.535.9001 ARS:cjh

Faxsimile: 858.597.1585

**Date: January 28, 2008**